The vaccine jointly developed by the pharmaceutical company AstraZeneca and the University of Oxford is being approved by a growing number of regulators, paving the way for its widespread use, especially in the developing world. The Australian drug regulator gave tentative approval for the COVID-19 AstraZeneca – Oxford vaccine on Tuesday, ahead of a national vaccination campaign that will begin next week. The Canberra government said it had ordered enough doses of the vaccine, to be manufactured in Australia, to cover the entire population of the country. The World Health Organization approved the vaccine for emergency use on Monday, which should allow developing countries wide access to the vaccine. AstraZeneca AZN, -1.19% has pledged not to profit from the sales of the vaccine, which is sold at the cheapest price of the vaccine available: at € 1.80 ($ 2.20) per dose, for example, in the European Union, according to Belgian health. Minister, compared to € 18 the dose of Moderna MRNA, -4.10% of vaccine and € 12 of Pfizer PFE, -0.12% –BioNTech BNTX, -3.43% one. The CEO of the Swedish-British group, Pascal Soriot, received the same 3% salary increase as the company’s staff for this year, raising his base salary to 1.33 million pounds (1.9 million dollars). ), wrote the Financial Times. But his bonus and long-term incentive program could take his salary package to more than £ 15 million. Even after French President Emmanuel Macron publicly raised his doubts about the AstraZeneca shooting in a media interview, his own health minister, Olivier Véran, was photographed taking it, in an attempt to reassure French public opinion about his efficacy and safety. Outlook: AstraZeneca sees doubts about the efficacy of its vaccine in the 65+ age group slowly dissipating, and its low price, coupled with ease of transport, storage and handling, could eventually make it one of the most used around the world.